<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7A72FF8-3FDA-40C7-8FB6-83EFDFBB7149"><gtr:id>F7A72FF8-3FDA-40C7-8FB6-83EFDFBB7149</gtr:id><gtr:name>Princeton University</gtr:name><gtr:address><gtr:line1>E-209A</gtr:line1><gtr:line2>Engineering Quad</gtr:line2><gtr:line4>Princeton</gtr:line4><gtr:line5>NJ 08544</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/780F450B-F300-4DFD-9931-3595F4E96170"><gtr:id>780F450B-F300-4DFD-9931-3595F4E96170</gtr:id><gtr:name>Karo Bio</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB"><gtr:id>7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB</gtr:id><gtr:name>University of Geneva</gtr:name><gtr:address><gtr:line1>University of Geneva</gtr:line1><gtr:line2>30 Quai Ernest-Ansemet</gtr:line2><gtr:postCode>CH-1211</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>School of Medical Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7A72FF8-3FDA-40C7-8FB6-83EFDFBB7149"><gtr:id>F7A72FF8-3FDA-40C7-8FB6-83EFDFBB7149</gtr:id><gtr:name>Princeton University</gtr:name><gtr:address><gtr:line1>E-209A</gtr:line1><gtr:line2>Engineering Quad</gtr:line2><gtr:line4>Princeton</gtr:line4><gtr:line5>NJ 08544</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/780F450B-F300-4DFD-9931-3595F4E96170"><gtr:id>780F450B-F300-4DFD-9931-3595F4E96170</gtr:id><gtr:name>Karo Bio</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB"><gtr:id>7DB68CCC-DD52-4CCA-AFFF-13BADAE898FB</gtr:id><gtr:name>University of Geneva</gtr:name><gtr:address><gtr:line1>University of Geneva</gtr:line1><gtr:line2>30 Quai Ernest-Ansemet</gtr:line2><gtr:postCode>CH-1211</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8A92553D-822E-4045-823C-9C8CCA624CD1"><gtr:id>8A92553D-822E-4045-823C-9C8CCA624CD1</gtr:id><gtr:firstName>Magnus</gtr:firstName><gtr:surname>Rattray</gtr:surname><gtr:orcidId>0000-0001-8196-5565</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0C4B94B2-E44D-4063-A353-2D66100D8ABC"><gtr:id>0C4B94B2-E44D-4063-A353-2D66100D8ABC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Loudon</gtr:surname><gtr:orcidId>0000-0003-3648-445X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DAAD1604-7A4E-44C3-9D8E-1B6DD4E39323"><gtr:id>DAAD1604-7A4E-44C3-9D8E-1B6DD4E39323</gtr:id><gtr:firstName>Laura</gtr:firstName><gtr:otherNames>Charlotte</gtr:otherNames><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0FEA1FE1-F4F6-4C91-833A-CA7CD3E1B59D"><gtr:id>0FEA1FE1-F4F6-4C91-833A-CA7CD3E1B59D</gtr:id><gtr:firstName>Toryn</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Poolman</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA7445F5-BE29-491E-AA50-E7C71EA640EE"><gtr:id>AA7445F5-BE29-491E-AA50-E7C71EA640EE</gtr:id><gtr:firstName>Anthony David</gtr:firstName><gtr:surname>Whetton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B14A701D-B5D2-406C-9D53-66ADF1C6B239"><gtr:id>B14A701D-B5D2-406C-9D53-66ADF1C6B239</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Ray</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL00254X%2F1"><gtr:id>09689604-98A2-41B2-ABD2-832679BD768B</gtr:id><gtr:title>Analysis of the pulmonary GR interactome, and functional validation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L00254X/1</gtr:grantReference><gtr:abstractText>Human inflammatory disease imposes a major financial and human cost world-wide. In particular inflammatory lung disease causes a major burden in lost productivity, treatment costs, morbidity, and premature mortality. A mainstay of therapy is the application of topical, and systemic glucocorticoids, but the response is variable between individuals, requiring high doses of powerful, synthetic drugs, which leads to off target effects. In addition, some patients fail to respond at all, for reasons which remain unclear, and some diseases are characteristically unresponsive, such as chronic obstructive pulmonary disease, and fibrosis. 
Development of new technology in our group now permits unbiased discovery approaches targeting the glucocorticoid response in pulmonary inflammation. Insights gained using in-vivo studies will be tested, and developed in-vitro, and finally we will apply these new insights across a broad panel of human pulmonary disease samples to identify patterns of expression with disease, and/or treatment response association. These emergent pathways, and proteins will form the basis for biomarker development, but more importantly will signal new ways in which the existing approaches using glucocorticoids can be improved, by designing new drugs, or considering additional treatments that can be used along with glucocorticoids adjunctive to gain therapeutic efficacy, and reduce off-target effects. These new insights will also stimulate new programmes of drug discovery, targeting emerging pathways regulating glucocorticoid action.
Our initial approach will measure the impact of inflammation in the lung on modification, and interactions of the glucocorticoid receptor (GR). We will study lung inflammation first, and then take these findings into lung cells for further characterization. We need to undertake the early discovery phase in lung, test the mechanisms of action using isolated lung cells, before testing the implications in human lung samples. We have optimized these approaches, and already have exciting new insights identifying a GR interacting protein, caveolin, as a major regulator of the pulmonary glucocorticoid effect. As many lung diseases show a time of day variation in their expression we have also examined the role of the circadian clock, the importance of which as a key homeostatic regulator of metabolism and inflammation is rapidly emerging. 
 
We are now able to genetically target GR deletion to the bronchial epithelium specifically, using a new and validated transgenic mouse strains. This will permit us to examine both the regulatory role of glucocorticoid action in this specific cell type for the first time, but will also refine our proteomics analyses to specific cells, by comparing the spectrum of modifications and interactions in intact lungs with those where GR has been deleted from the bronchial epithelium.
Having refined our analysis to glucocorticoid action in the bronchial epithelium we will apply an unbiased approach to measure the impact of inflammatory signaling on GR function. This will use isolated bronchial epithelial cells, to reduce complexity, and as a tractable model for testing hypotheses as they emerge from the whole lung analysis. In the cells we will validate emerging protein interactions, and modifications, and analyze all the sites of gene regulation that are driven by the GR, so permitting analysis of the full spectrum of GR activity in this important cell type for the first time. Moreover, this analysis will allow us to discover how inflammation impacts on GR function.
We will analyse all the molecular results obtained in lung, and from this identify signaling networks responsible for regulating the inflammatory effect. These will be refined using lung cells, and then the expression of these mediators will be tested in human lung disease samples, to find new explanations for disease, and its response to treatment.</gtr:abstractText><gtr:technicalSummary>Lung disease, frequently with a major inflammatory component, is a major human health burden, in terms of cost, and morbidity/mortality. Glucocorticoids are widely used to treat lung inflammation, but the treatment response is variable. In addition some inflammatory diseases do not respond to glucocorticoids.
We have developed novel approaches to comprehensively measure the GR post-translational modification, and protein interactome in lung tissue. This permits, for the first time, sampling of the consequences of inflammation, and drug treatment within the target tissue under physiological conditions. As a consequence of our pilot work we have already discovered an unexpected role for the protein caveolin as a GR regulator, and seek to explore the mechanisms responsible at an early stage. We have preliminary data associating changes in pulmonary inflammatory reactivity with circulating endogenous glucocorticoids, and therefore also seek to explore how these two systems interact, using in-vivo and in-vitro approaches.
We move to cell-type specific targeting of GR expression to anchor our observations to the bronchial epithelial cells, permitting further proteomics analysis in defined cell populations from whole animal challenges. We will explore the mechanisms of GR regulation, and the consequences for GR function using cell models, and molecular analysis at two levels, the GR cistrome and transcriptome. We have unrivalled expertise in computational biology required to manage these multidimensional datasets at applicant, and collaborator level, and outcomes will include both systems level analysis, and the generation of testable hypotheses. These latter will be pursued using cell culture models, before return to experimental pulmonary inflammation.
We will translate our findings to human lung disease by associating changes in emergent target gene expression, and protein in our comprehensive lung tissue archive.</gtr:technicalSummary><gtr:potentialImpactText>The research questions posed within this proposal are of major interest to ACADEMIC GROUPINGS in Biological,Biomedical Sciences, and Clinical science. The academic community will benefit from elucidation of novel mechanisms whereby innate immunity regulates and interacts with the principal endogenous anti-inflammatory regulator, the glucocorticoid receptor, on a molecular and anatomical level. As such, research findings will impact greatly on the HEALTH CARE COMMUNITY. We will disseminate findings by publishing primary papers and reviews in high impact journals, and presenting work at national and international meetings. We anticipate that the proposed work will produce 2-4 high-quality primary research papers.

All findings will be of high interest to the GENERAL PUBLIC due to the prevalence of inflammatory lung disease, and widespread usage of glucocorticoid medications, which often engender concern in patients due to the risk of side-effects. At its most basic, the work will engage sections of the populous who wish to learn about their health and human physiology. Research findings will be delivered to the general public through public engagement activities (e.g. annual science open days at the UoM, Caf&amp;eacute; Scientifique presentations), as well as through mass media. For example, several of our recent papers have been reported widely in national and international newspapers, on local radio, and on the intranet following press releases issued by the University of Manchester and BBSRC.

The proposed research is of interest to PHARMACEUTICAL COMPANIES due to direct implications for human inflammatory disease affecting the lung, and other organs. Pharmaceutical industry investment into glucocorticoid regulating compounds, and other anti-inflammatory approaches is massive, due to the frequent involvement of inflammatory mechanisms in a wide range of human diseases. In the context of &amp;quot;building partnerships to enhance take-up and impact, thereby contributing to the econoic competitiveness of the United Kingdom&amp;quot;, our laboratories have taken a major lead within the extensive community of researchers at the University of Manchester by developing significant interactions and links with GSK and a joint nuclear receptor Biology Programme. 

Industrial interest is evidenced by the substantive contributions to this application arising from the secondment of Stuart Farrow from GSK to work on the joint programme, and the access to tool compound libraries, and bioinformatic databases of gene expression data in human tissue and disease.

The Faculty of Medical and Human Sciences at Manchester has taken a strong proactive role in developing links with major pharmaceutical companies, enhancing public communication of science, as well as identification and development of commercialisation opportunities. There are dedicated members of staff employed within the Faculty to assist in these areas. A recent success is the establishment of the Manchester Centre for Collaborative Inflammation Research, director Prof T Hussell, a collaborator. This centre draws in substantial cash investment from both GSK and AZ in inflammation research. Our programme will link to the centre, maximising commercial exploitation potential.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>654538</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute of Biochemistry</gtr:department><gtr:description>max quant summer school</gtr:description><gtr:id>28B1AF2E-7AF8-4DCE-8F90-BB0C42B64646</gtr:id><gtr:impact>not yet</gtr:impact><gtr:outcomeId>58bffb40a4be30.32002149-1</gtr:outcomeId><gtr:partnerContribution>this is an interactive summer school which provides hands on training and collaborative links in computational biology especially as applied to proteomics.</gtr:partnerContribution><gtr:piContribution>Max quant summer school oxford UK 2016

Juergen Cox, writer of software and scripts, and now a collaborator. Visiting with us 10th March 2017</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princeton University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>metadherin as a major regulator of glucocortcoid action</gtr:description><gtr:id>A4C0C463-2EB3-4E8B-BE63-0863C1C36FCB</gtr:id><gtr:impact>So far the outputs are training but we are writing up the paper now.</gtr:impact><gtr:outcomeId>56d95d8403fe69.11033378-1</gtr:outcomeId><gtr:partnerContribution>Our partners had the mouse, and did the in-vivo studies for us.</gtr:partnerContribution><gtr:piContribution>We discovered a role for metadherin in glucocortiocid action. Yibin Kang had the knockout mouse, and we have been working together to work out the physiological consequences of this novel interaction.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>Established new collaboration with Prof Angela Simpson at NorthWest Regional Lung Centre</gtr:description><gtr:id>D3A6AB93-5150-4DF2-9414-1A698F3AD0D3</gtr:id><gtr:impact>not yet</gtr:impact><gtr:outcomeId>54478f327fecd3.88035853-1</gtr:outcomeId><gtr:partnerContribution>They are helping with ethics, patient recruitment, recovery and processing of human lung.</gtr:partnerContribution><gtr:piContribution>We are identifying new pathways operating in the inflamed lung. We are now testing to see if these operate in chronic human lung diseases.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karo Bio</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Development of novel glucocorticoid ligands for inflammatory lung disease.</gtr:description><gtr:id>59DF94E6-AAC0-4FCD-9DE6-3165A9BAE5A7</gtr:id><gtr:impact>not yet</gtr:impact><gtr:outcomeId>541fd1d81880b1.02129173-1</gtr:outcomeId><gtr:partnerContribution>They provided cash, and contribution in kind in support of an MRC CASE award.</gtr:partnerContribution><gtr:piContribution>We developed a proposal to access the KaroBio compound library, and some specific technologies, in particular nuclear receptor crystallography, in pursuit of new ligands for the glucocorticoid receptor</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Anna Nicoleau</gtr:description><gtr:id>6C7CEE50-32FE-4789-B789-628C25A46D23</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d9919a1da1e8.00738946-1</gtr:outcomeId><gtr:partnerContribution>Anna and her team analysed serum for inflammatory lipid species</gtr:partnerContribution><gtr:piContribution>We ran a study in patients with rheumatoid arthritis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princeton University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>yibin kang</gtr:description><gtr:id>0F2B235A-EA35-40DA-81F9-E1235FE0FCDD</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>58bffbbc578de4.76855491-1</gtr:outcomeId><gtr:partnerContribution>they provided mice and did the physiology expts for us.</gtr:partnerContribution><gtr:piContribution>access to transgenic mice and in-vivo experimentation protocols</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Geneva</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Molecular Biology</gtr:department><gtr:description>Ueli Schibler</gtr:description><gtr:id>04E1C388-BB30-4572-A5CB-F5200B9B8A7E</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d99220c24ee9.14728208-1</gtr:outcomeId><gtr:partnerContribution>Our partners provided us with STAR-PROM technology to measure serum circadian factors</gtr:partnerContribution><gtr:piContribution>We collected serum from patients with rheumatoid arthritis. We discovered a new circadian signature.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>optimiser programme for business engagement</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F0522ECA-FACC-456A-9CC1-8780EEA9534F</gtr:id><gtr:impact>Optimizer programme: business development training 2016-2017</gtr:impact><gtr:outcomeId>58bffce7aaff59.92187691</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>public engagement</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>851CD118-5806-4534-AB22-CA95F437B7EF</gtr:id><gtr:impact>Reclaim Project: Youth Mentor 2017 , Lead&amp;amp;Activism weekends (NOV2016/ FEB2017)</gtr:impact><gtr:outcomeId>58bffc279271d6.94623898</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC breakfast, and new channel, and five live phone in.  on 4th November 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>904F46F0-C961-4D44-96EC-42D080757B6B</gtr:id><gtr:impact>I discussed the impact of shift work on the body clock, and the consequences for human health.

I have had numerous contacts from people engaged in shift work asking for advice.</gtr:impact><gtr:outcomeId>545b4742768b84.98032630</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>academic presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>59DBEE94-1166-4CF2-9929-9ABC48682586</gtr:id><gtr:impact>Clcok club presentation.

&amp;quot;newly rhythmic processes emerge in active rheumatoid arthritis.&amp;quot;</gtr:impact><gtr:outcomeId>58bffc95546a23.04755405</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>89000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of the clock in allergic asthma</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>7ACFE11C-1134-4B00-960E-CDD7167BA56F</gtr:id><gtr:outcomeId>54478fb085c2f7.85817140</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>675328</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P011853/1</gtr:fundingRef><gtr:id>FC3F27A6-33C2-4A8C-97FE-E5790D12CD14</gtr:id><gtr:outcomeId>58bff3eb9259b4.75457233</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>wellcome investigator</gtr:description><gtr:end>2021-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>n/a</gtr:fundingRef><gtr:id>F26ADF12-A95F-4C00-B2C2-B9A78943DA5E</gtr:id><gtr:outcomeId>56d95ca45d1327.63195006</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>844160</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>research grant</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>95499B99-27DE-441E-A40D-ED3D84BE8DCA</gtr:id><gtr:outcomeId>58b9a21e354834.69599379</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>269390</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>clinical research fellowship</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>08C3801D-5A20-45AC-8D71-C4629D04337A</gtr:id><gtr:outcomeId>58b9a2921cd4d8.75033425</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>deputy chair MRC Clinical Research Training Fellowship Panel</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BE0353B9-1240-4B91-829E-7B968BFFA3C0</gtr:id><gtr:impact>I have contributed to the assessment, selection and mentoring of clinical fellows funded by MRC over the last seven years, initially as panel member then chair.</gtr:impact><gtr:outcomeId>56d9953f816b80.55827946</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a rapid, simple and direct method of capturing the nuclear receptor protein interactome, and analysing it using a workflow which culminates in tandem mass spec. This has revealed a number of novel targets, and potential pathways which we are now testing.</gtr:description><gtr:id>F3C2CDDE-C055-42AC-8BA7-BA4A39FD47FB</gtr:id><gtr:impact>we are completing work on our first manuscript, which will detail, and validate the method.</gtr:impact><gtr:outcomeId>54479059474943.15651403</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>rapid high fidelity capture of nuclear receptor interactome</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2B844067-3206-4FD8-8EE9-50F5BA623B6E</gtr:id><gtr:title>A matter of time: study of circadian clocks and their role in inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f27aac886052288574ed14759f180b4"><gtr:id>8f27aac886052288574ed14759f180b4</gtr:id><gtr:otherNames>Carter SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>58b9a52a265e27.13668577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7BE2180-709D-42CF-8D14-84C29AF375B8</gtr:id><gtr:title>CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/726b00d39a70e3a6655fbb015c0e64cb"><gtr:id>726b00d39a70e3a6655fbb015c0e64cb</gtr:id><gtr:otherNames>Grundy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>545b604b708725.22835980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>554FAA39-0CA5-4910-936A-2C0CE30DC878</gtr:id><gtr:title>A non-transcriptional role for the glucocorticoid receptor in mediating the cell stress response.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e1bceaa6361241eb2c3d3d3f5583a19"><gtr:id>3e1bceaa6361241eb2c3d3d3f5583a19</gtr:id><gtr:otherNames>Ptushkina M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a8d86c45a4f06.37302764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>749D3CB1-E1EB-43DA-8D6B-CB0709321A63</gtr:id><gtr:title>The methyltransferase WBSCR22/Merm1 enhances glucocorticoid receptor function and is regulated in lung inflammation and cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f19c5a4053b0434d43cbf8f7b436eddc"><gtr:id>f19c5a4053b0434d43cbf8f7b436eddc</gtr:id><gtr:otherNames>Jangani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545b61e86dcc89.86305863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEB23436-8B7B-42BD-A561-40271CBB73E4</gtr:id><gtr:title>The N-terminal transactivation domain of the glucocorticoid receptor mediates apoptosis of human small cell lung cancer cells.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ced39d1f99179e5ffe5edc968b042a67"><gtr:id>ced39d1f99179e5ffe5edc968b042a67</gtr:id><gtr:otherNames>Singh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>545b61e8964aa5.39446003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDBA0B4C-BB73-4196-9203-1E34136501FB</gtr:id><gtr:title>An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbe77509019047feebf5c8d6e8a47b0d"><gtr:id>fbe77509019047feebf5c8d6e8a47b0d</gtr:id><gtr:otherNames>Gibbs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>545b600716fad0.29576280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B68EFF6-0525-4216-A50F-5C411D0B6794</gtr:id><gtr:title>Functioning of the hypothalamic-pituitary-adrenal and growth hormone axes in frequently unexplained disorders: results of a population study.</gtr:title><gtr:parentPublicationTitle>European journal of pain (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2d1c95905c414dc516278de939e82f"><gtr:id>ab2d1c95905c414dc516278de939e82f</gtr:id><gtr:otherNames>Aggarwal VR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-3801</gtr:issn><gtr:outcomeId>545b61e7f12451.97295486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DE79C86-AC89-4DD9-A574-29828E524611</gtr:id><gtr:title>Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8e11abf417df64c2619312c232c8bf"><gtr:id>2b8e11abf417df64c2619312c232c8bf</gtr:id><gtr:otherNames>Matthews LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d9900dd5af09.20773857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29ECC379-FA67-4342-805A-E33CAB5D2FB7</gtr:id><gtr:title>Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodology.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d30a4390637aeb5bab26bf7995e81d36"><gtr:id>d30a4390637aeb5bab26bf7995e81d36</gtr:id><gtr:otherNames>Higham A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>545b604b44ffb2.36291382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F119DCB1-FAFC-4795-B50F-164FE2474F15</gtr:id><gtr:title>Ectopic Cushing's syndrome secondary to olfactory neuroblastoma.</gtr:title><gtr:parentPublicationTitle>Acta neurochirurgica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ee5babd6aada8b275af983e29e4c2a2"><gtr:id>4ee5babd6aada8b275af983e29e4c2a2</gtr:id><gtr:otherNames>Yu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0001-6268</gtr:issn><gtr:outcomeId>5a8d86c40a6773.32471653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DDF9F5-E028-4B4B-A724-6A62D4A32CB4</gtr:id><gtr:title>Glucocorticoid receptors in lung cancer: new perspectives.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d556cacc88b8042130f50f19a9bf08c"><gtr:id>0d556cacc88b8042130f50f19a9bf08c</gtr:id><gtr:otherNames>Taylor KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>58b9a52ab7f474.47642821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22987AD1-DC03-472F-BC2D-CDED73110C8F</gtr:id><gtr:title>Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b9a52b540382.02444405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF8C5FD7-3AB1-42F4-8880-E941B3DA0C8B</gtr:id><gtr:title>Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec1a96c0bd54455855f22500a0126aff"><gtr:id>ec1a96c0bd54455855f22500a0126aff</gtr:id><gtr:otherNames>McCaffrey JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a8d86c4e04cd0.17794539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7918E9E5-5336-4803-A399-8084E431CD6C</gtr:id><gtr:title>Glucocorticoid receptor isoforms direct distinct mitochondrial programs to regulate ATP production.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30825f36d99b29dc63708cd404a04d28"><gtr:id>30825f36d99b29dc63708cd404a04d28</gtr:id><gtr:otherNames>Morgan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b9a52a89ded5.24718386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B13F5081-79BA-40EE-A551-222080044596</gtr:id><gtr:title>Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.</gtr:title><gtr:parentPublicationTitle>Seminars in arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6691bf1e25c210d6243d15495430ede1"><gtr:id>6691bf1e25c210d6243d15495430ede1</gtr:id><gtr:otherNames>Joseph RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0049-0172</gtr:issn><gtr:outcomeId>58b9a52b100d59.28047774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC4F790F-A1D0-4069-AB1F-DAFDC0D80D19</gtr:id><gtr:title>The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1079-9907</gtr:issn><gtr:outcomeId>545b61e8460ca9.28626393</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L00254X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>